Drug Trial Radar · NCT07265947
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
285
Planned (sponsor's estimate)
Start
Dec 22, 2025
Primary completion
Oct 2030
Study completion Nov 2030
Sponsor
- Lead sponsor
- Tyra Biosciences, IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
Conditions
- Low Grade Upper Tract Urothelial Carcinoma
Interventions
Dabogratinib (TYRA-300) 60mgDrug
Self-administered 60mg dose Oral tablet(s) given daily
Dabogratinib (TYRA-300) 80mgDrug
Self-administered 80mg dose Oral tablet(s) given daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the efficacy of Dabogratinib in LG UTUC FGFR3+ participants (proportion of participants with a CR within 6 months out of all LG UTUC FGFR3+ participants)Time frame: within 6 months
Locations
36 sites in 4 countries. Site status is shown where the registry gives one.
Loma Linda University (LLU) - Loma Linda University Medical Center (LLUM)
Loma Linda, California · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
The Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
The University of Chicago
Chicago, Illinois · Recruiting
Duly Health and Care Chicago
Lisle, Illinois · Recruiting
Urology of Indiana, LLC
Greenwood, Indiana · Recruiting
Indiana University (IU) Health Physicians - Urology
Indianapolis, Indiana · Recruiting
First Urology
Jeffersonville, Indiana · Recruiting
Greater Boston Urology - Plymouth Care Center
Plymouth, Massachusetts · Recruiting
University of Michigan Health System (UMHS)
Ann Arbor, Michigan · Recruiting
Michigan Healthcare Professionals - William Beaumont University Hospital
Royal Oak, Michigan · Recruiting
Urology of St. Louis
St Louis, Missouri · Recruiting
Summit Health - Washington Township
Sewell, New Jersey · Recruiting
Albany Medical College
Albany, New York · Recruiting
Associated Medical Professionals of NY, PLLC
Syracuse, New York · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio · Recruiting
Central Ohio Urology Group
Gahanna, Ohio · Recruiting
Penn Medicine Radnor
Radnor, Pennsylvania · Recruiting
Medical University of South Carolina (MUSC)
Mt. Pleasant, South Carolina · Recruiting
Urology Associates, P C
Nashville, Tennessee · Recruiting
Urology Austin - Apex Cancer Care - Austin
Austin, Texas · Recruiting
The University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Hopital Pitie-Salpetriere
Paris, France · Recruiting
Hôpital Européen Georges Pompidou (HEGP)
Paris, France · Recruiting
CHU de Saint-Etienne - Hopital Bellevue
Saint-Etienne, France · Recruiting
Hadassah University Hospital - Ein Kerem
Jerusalem, Israel · Recruiting
Meir Medical Center
Kfar Saba, Israel · Recruiting
Edith Wolfson Medical Center
Holon, Tel Aviv, Israel · Recruiting
Chaim Sheba Medical Center
Ramat Gan, Tel Aviv, Israel · Recruiting
Tel Aviv Sourasky Medical Center
Tel Aviv, Tel Aviv, Israel · Recruiting
Hospital Universitario Puerta del Mar
Cadiz, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Universitari i Politècnic La Fe
Valencia, Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.